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High-throughput screeningRational design ofmulti-targeteddrug combinations is a promising strategy to tackle thedrug resistance problem
formany complex disorders. A drug combination is usually classiﬁed as synergistic or antagonistic, depending on
the deviation of the observed combination response from the expected effect calculated based on a reference
model of non-interaction. The existing referencemodels were proposed originally for low-throughput drug com-
bination experiments,whichmake themodel assumptions often incompatiblewith the complex drug interaction
patterns across various dose pairs that are typically observed in large-scale dose–response matrix experiments.
To address these limitations, we proposed a novel reference model, named zero interaction potency (ZIP),
which captures the drug interaction relationships by comparing the change in the potency of the dose–response
curves between individual drugs and their combinations.We utilized a delta score to quantify the deviation from
the expectation of zero interaction, andproved that a delta score value of zero implies both probabilistic indepen-
dence and dose additivity. Using data from a large-scale anticancer drug combination experiment, we demon-
strated empirically how the ZIP scoring approach captures the experimentally conﬁrmed drug synergy while
keeping the false positive rate at a low level. Further, rather than relying on a single parameter to assess drug in-
teraction, we proposed the use of an interaction landscape over the full dose–response matrix to identify and
quantify synergistic and antagonistic dose regions. The interaction landscape offers an increased power to differ-
entiate between various classes of drug combinations, andmay therefore provide an improvedmeans for under-
standing their mechanisms of action toward clinical translation.
© 2015 Yadav et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural
Biotechnology. This is an open access article under the CCBY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Drug combinations that consist of multiple chemical agents have
shown great promises to improve efﬁcacy and overcome resistance for
treating complex and refractory diseases. In cancer therapy, for exam-
ple, an effective drug combinationmay targetmultiple proteins or path-
ways that are aberrantly activated in disease, but not in normal cells,
and thus reduces the chances that a cancer will develop drug resistance
by activating bypassing pathways, when compared to standard mono-
therapies [1–3]. To accelerate the discovery of novel drug combinations
using an empirical approach, preclinical drug screening platforms have
been developed that allow for assaying the phenotypic endpoint re-
sponses in vitro or ex vivo. With high-throughput techniques, it has be-
come possible to systematically evaluate the pairwise combinations
from a large collections of both approved and investigational chemical
compounds [4]. Such functional screening approaches have increasingly
led to advances in the characterization of drug–drug interactions foron behalf of the Research Network ofmultiple diseases, and prioritization of effective and safe drug combina-
tions for further clinical examination.
To quantify the interaction between drugs, the observed combina-
tion response is often compared to the expected effect under the as-
sumption of non-interaction predicted by a reference model. When
the combination response is greater than what is expected, then the
combinations is classiﬁed as synergistic, while antagonism is concluded
when the combination produces less than the expected effect. Current-
ly, there are three popular classes of reference models: Highest single
agent (HSA) model [5], Loewe additivity model [6] and Bliss indepen-
dence model [7]. These reference models, together with many of their
subsequent variants and extensions, have been developed based on dif-
ferent assumptions about the expected effect of non-interaction. The
HSA model, or Gaddum's non-interaction model, assumes that the ex-
pected combination effect equals to the higher individual drug effect
at the dose in the combination, representing the idea that a synergistic
drug combination should produce additional beneﬁts on top of what
its components can achieve alone. Inmanypreclinical drug combination
studies, however, even a drug combined with itself can easily produce
an excess over HSA. For more stringent synergy classiﬁcation, theComputational and Structural Biotechnology. This is an open access article under the CC BY
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Fig. 1. The concept of Combination Index (CI) based on the Loewe additivity model. (A)
Loewe additivity with CI = 1 can be visualized as a straight line at a two-dimensional
isobologram with the doses of drug 1 and drug 2 as coordinates. A synergistic (CI b 1)
and antagonistic (CI N 1) drug combination will be positioned below and above the addi-
tivity line, respectively (adopted from [9]). (B) Loewe additivity model cannot directly as-
sess such drug interaction in which a combination effect is higher than the achievable
effect of the individual drugs, even though by intuition one would expect a clinically rele-
vant synergy in such cases.
505B. Yadav et al. / Computational and Structural Biotechnology Journal 13 (2015) 504–513Loewe additivity and Bliss independencemodels are beingwidely used.
The Loewe additivity model deﬁnes the expected effect as if a drug was
combinedwith itself, while the Bliss independencemodel utilizes prob-
abilistic theory tomodel the effects of individual drugs in a combination
as independent yet competing events. Due to the inherent differences in
themodel assumptions, there is a lack of consensus onwhich references
model one should use in an unbiased and statistically robustmanner. As
pointed out by many others [8–10], there is still no standardized guide-
line on how to choose the optimal reference model.
Apart from the disagreement among the theoretical aspects, there
are considerable pragmatic challenges on how to apply the Loewe and
Blissmodels for analyzing drug combination experiments. First, the cur-
rently available scoring tools are rather limited and suboptimal for a
high-throughput setting. For instance, CompuSyn is one of the most-
cited standalone software packages used to calculate the interaction
score based on the Loewemodel [11]. However, it only allows for aman-
ual input of dose–response data for one drug combination at a time, and
thus becomes quickly unfeasible for analyzing large-scale drug screen-
ing data which typically consists of hundreds of combinations. For
implementations of the Loewe model, there are a few packages in R,
such as drc [12] and SYNERGY [13], but these packages are not ﬂexible
enough to handle the noise in a typical high-throughput drug screen,
which tend to invalidate many of the widely used curve ﬁtting func-
tions. As a result, drugs that have negative or irregular responses may
easily lead to a ﬁtting error that breaks down the program. Secondly,
many existing methods utilize a summary interaction score to charac-
terize the overall drug interaction effect, which may be sufﬁcient for
the initial ﬁltering of potential synergistic drug combinations. However,
a follow-up conﬁrmatory screen often utilizes a dose–response matrix
for which a single interaction parameter cannot effectively capture the
synergies and antagonisms that may occur within speciﬁc dose regions
only. With an increasing number of drug combinations that have been
tested using the dose–response matrix design, there is a critical need
to develop efﬁcient and robust computational tools to systematically
evaluate and visualize the drug interaction at the level of individual
dose combinations.
To address these challenges, we introduced a novel referencemodel,
named zero interaction potency (ZIP), which overcomes many of the
limitations of the existing models. By combining the advantages of
both the Loewe and Bliss models, the ZIP model assumes that two
non-interacting drugs are expected to incur minimal changes in their
dose–response curves. We calculated a delta score to quantify the devi-
ation from the expectation of ZIP for a given dose pair and utilized the
average delta over a dose–response matrix as a summary interaction
score for a drug combination. To test this model, we analyzed the data
from a recent high-throughput drug combination study in cancer [14].
We showed that the ZIP-based delta scoring approach tolerates well
the experimental noise in such combination screens and provides an
improved solution for identifying true synergistic interactions, while
keeping the false positive rate relatively low. Further, we demonstrated
how an interaction landscape visualization of delta scores can facilitate
the identiﬁcation of clinically relevant drug synergywithin speciﬁc dose
regions. We believe our drug interaction scoringmethod has the poten-
tial to allow for a systematic evaluation of drug combinations in a high-
throughput setting, and may therefore become increasingly beneﬁcial
for drug combination discovery and development in the future
experiments.
2. Methods
2.1. Relationships Between the Existing Reference Models of Non-
Interaction
Consider a typical drug screening experiment where the drug's ef-
fect y is expressed on a continuous scale between 0 and 1, i.e.
0 ≤ y ≤ 1. In a cell-based drug screening, y is usually measured as thefractional inhibition of cell growth, or percentage of cell death. Note
that some studies alternatively consider the drug's effect as a percent-
age of survival or viability, which is opposite to our deﬁnition, but the
subsequent mathematical derivation also applies by replacing y with 1
– y. Suppose that one drug produced an effect y1 at dose x1 and the
other drug produced an effect y2 at dose x2 while combining them pro-
duced yc. We follow a common three-class nomenclature to distinguish
the interactions between the two drugs. Namely a drug interaction can
be classiﬁed as synergistic, antagonistic or non-interactive, depending
on whether yc is greater or less than the expected effect under the as-
sumption of non-interaction. To calculate the expected effect, one
needs to utilize a reference model that is based on certain principles
or assumptions. There are three frequently-used reference models:
Highest single agent (HSA), Bliss independence and Loewe additivity.
TheHSAmodel states that the expected combination effect equals to
the higher effect of individual drugs, i.e. yHSE = max(y1, y2). Therefore,
any additional effect over the higher single drug will be considered as
a HSA synergy [5].
The Bliss independence model [7] assumes a stochastic process in
which two drugs elicit their effects independently, and the expected
combination effect can be calculated based on the probability of inde-
pendent events as
yBLISS ¼ y1 þ y2−y1y2: ð1Þ
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must satisfy
x1
X1LOEWE
þ x2
X2LOEWE
¼ 1; ð2Þ
where X1LOEWE and X2LOEWE are the doses of drug 1 and 2 alone that pro-
duce yLOEWE[6]. In a Cartesian coordinate system, with the axes
representing the individual drug doses, Eq. (2) can be represented as a
straight line of additivity connecting X1LOEWE and X2LOEWE (Fig. 1A).
This is also called the Isobole of additivity [15]. Note that a hidden as-
sumption has been made that the individual drug dose–responses
must be monotonic, i.e., a drug alone produces yLOEWE at a higher dose
than in the combination. Suppose that the observed combination effect
yc N yLOEWE then we have Xc1 N XLOEWE1 and Xc2 N XLOEWE2 , where Xc1 and Xc2
are deﬁned similarly as the doses of drug 1 and 2 alone that produce yc.
This leads to
x1
X1c
þ x2
X2c
b1: ð3Þ
The left part of Eq. (3) is also called Combination Index (CI), with
CI b 1 corresponding to yc N yLOEWE and thus a Loewe synergy.
The Loewe additivity model can also take a parametric form. One
way to describe the dose–response curves is a commonly-used 4-pa-
rameter log-logistic (4PL) function
y ¼ Emin þ Emax
x
m
 λ
1þ xm
 λ : ð4Þ
Here, Emin and Emax are the minimal andmaximal effects of the drug
(0 ≤ Emin b Emax ≤ 1);m is the dose that produces the midpoint effect of
Emin + Emax, also known as relative EC50 or IC50, and λ(λ N 0) is the
shape parameter indicating the sigmoidicity or slope of the curve. In ad-
dition to much mathematical and statistical convenience, the 4PL func-
tion leads to an odds ratio of the affected fa and unaffected fu fractions as
a logit model
f a
f u
¼ y−Emin
Emax−y
¼ x
m
 λ
: ð5Þ
Eq. (5) corresponds to the widely used Chou and Talalay median ef-
fect equation, which ﬁts to the expectation of themass-action law prin-
ciple that dictates many biological processes such as cell growth or
ligand-binding interactions [9].
Following this line of parameterization, we can calculate the dose
that produces a given effect as
x ¼ m y−Emin
Emax−y
 1=λ
: ð6Þ
Assuming λ= 1, Emin = 0 and Emax = 1, Eq. (6) leads to a constant
dose ratio for the two drugs that alone produce the same effect, i.e., x1 /
x2 = m1 / m2, which is called the constant relative potency model that
has been explored before [15].
From Eq. (6), one can derive the analytical form of Eq. (2) for yLOEWE
as
x1
m1
yLOEWE−E
1
min
E1max−yLOEWE
 1=λ1 þ
x2
m2
yLOEWE−E
2
min
E2max−yLOEWE
 1=λ2 ¼ 1; ð7Þ
for which a numerical nonlinear solver can be used to determine yLOEWE
for (x1, x2).The Combination Index can be also derived in an analytical form as
CI ¼ x1
m1
yc−E
1
min
E1max−yLOEWE
 1=λ1 þ
x2
m2
yc−E
2
min
E2max−yLOEWE
 1=λ2 : ð8Þ
Further extending Eq. (8), [8] proposed an interaction index a de-
ﬁned in the following equation:
1 ¼ x1
m1
yc−E
1
min
E1max−yc
 1=λ1 þ
x2
m2
yc−E
2
min
E2max−yc
 1=λ2
þ α x1x2
m1m2
yc−E
1
min
E1max−yc
 1=2λ1 yc−E2min
E2max−yc
 1=2λ2 ; ð9Þ
with case a = 0 corresponding to CI = 1 and thus equivalent to the
Loewe additivity.
Consider a sham experiment, where two identical drugs are com-
bined, i.e.,m1 = m2 and λ1 = λ2, then Eq. (7) can be simpliﬁed as
x1 þ x2
m yLOEWE−EminEmax−yLOEWE
 1=λ ¼ 1; ð10Þ
from which one can derive that
yLOEWE ¼
Emin þ Emax x1þx2m
 λ
1þ x1þx2m
 λ : ð11Þ
This shows that yLOEWE is equal to the single drug response at dose
x1+ x2 in a sham experiment, which has been an important justiﬁcation
of the Loewe additivity model. However, for actual drug combination
studies where two drugs are unlikely identical, such an additivity impli-
cation according to Eq. (11)might become less intuitive, and sometimes
it can be even problematic. For example, yLOEWE is expected to be lower
than the achievable effects of both individual drugs according to Eq. (7),
i.e., yLOEWE bmin(Emax(1) , Emax(2) ). If we observe a combination effect which
is not observed in one of the individual drugs, we do not have a deﬁnite
answer for yLOEWE. In fact, this limitation of the Loewe additivity model
is irrespective ofwhat the parameterizationmight be. Consider a simple
casewhere y1=0.3, y2=0.4 and yc=0.6, andwe know that Emax1 =0.4
and Emax2 = 0.5.We ask the following question:what is the expected ef-
fect of non-interaction and how much is the synergy for yc? Both HSA
and Bliss can provide a sound answer but with the Loewe additivity
model the solution is not straightforward. Following the sham experi-
mental principle, one might conclude either that yLOEWE = 0.4 or
yLOEWE = 0.5 depending on which individual drugs one focuses on.
The upper limit of yLOEWE does not seem to be sufﬁciently discussed
in the literature. One reason might be that traditionally one would start
testing a drug combination only if the individual drugs were already
known to be effective. This would lead to the increase of Emax1 and
Emax
2 close to 1,which allows that yLOEWE can be calculated for themajor-
ity of the tested dose pairs. In a high-throughput setting, however, we
often do not know beforehand whether the drugs in a combination
are effective or not within the tested dose ranges. If we see a combina-
tion that produces a stronger effect than what an individual drug can
achieve within the dose range alone, by intuition, we would consider
it as a signiﬁcant synergy. For this scenario, unfortunately, the Loewe
additive model cannot be utilized directly due to the lower boundaries
for individual drugs (Fig. 1B).
2.2. Zero Interaction Potency Model for Evaluating Drug Interactions
Given the effect y1 at dose x1 for drug 1 and y2 at dose x2 for drug 2,
we rephrased the question: what is the expected combination effect for
a dose pair (x1, x2)? Both the HSA and the Bliss independence models
give a point estimate using different assumptions while the Loewe
507B. Yadav et al. / Computational and Structural Biotechnology Journal 13 (2015) 504–513additivity model considered the dose–response curves of individual
drugs. We took one step further by considering not only the dose–re-
sponse curves for individual drugs but also for their combinations and
derive a score to quantify their interactions. We considered a 4-param-
eter log-logistic function as deﬁned in Eq. (4) to model the dose–re-
sponse curves. The logistic function has been commonly utilized in the
characterization of complex dose–response relationship as it offers ﬂex-
ibility even for ﬁtting a ﬂat dose–response. For the sake of simplicity in
the remaining derivations, we assumed further that the individual
drugs are equally effective to reach the complete inhibition of the cell
growth, i.e., Emin = 0 and Emax = 1. The derivation of ZIP using the full
4-parameter logistic function is provided in Appendix A3. We took the
perspective of zero potency shift for non-interaction, i.e., an expected
combination effect should not change the potency of the individual
drug dose–response curves. Take drug 1 as an example, the single
dose–response relationships follows:
y ¼
x
m1
 λ1
1þ xm1
 λ1 : ð12Þ
When drug 2 at dose x2 is added to drug 1, it will change the dose–
response curve accordingly. If there is no interaction, then adding
drug 2 should simply increase the baseline level of drug 1, while incur-
ring no potency shift in the dose–response curve. This would imply that
m1 and λ1 remain unchanged. The dose–response curve for drug 1 in the
combination then becomes
y1←2 ¼
y2 þ xm1
 λ1
1þ xm1
 λ1 : ð13Þ
Here, we used 1← 2 to emphasize the drug combination as drug 1-
centric, i.e., adding drug 2 to drug 1 to examine the change in dose–re-
sponse curve of drug 1. The expected combination effect at dose pair (x1,
x2) can be derived from Eq. (13) as
y1←2ZIP ¼
y2 þ x1m1
 λ1
1þ x1m1
 λ1 ¼
1
1þ m2x2
 λ2 þ x1m1
 λ1
1þ x1m1
 λ1 : ð14Þ
Similarly, the expected combination effect from the drug-2 centric
viewpoint by adding drug 1 to drug 2 becomes
y2←1ZIP ¼
y1 þ x2m2
 λ2
1þ x2m2
 λ2 ¼
1
1þ m1x1
 λ1 þ
x2
m2
 λ2
1þ x2m2
 λ2 : ð15Þ
A simple algebra shows that yZIP1← 2 = yZIP2← 1, which reﬂects the intui-
tion that the expected combination effect should be independent of the
order of adding individual drugs in the combination. Appendix A1
shows how yZIP can be factorized as a multiplicative of single dose–re-
sponse curves, which implies the probabilistic independence between
the two drugs:
yZIP ¼
x1
m1
 λ1
1þ x1m1
 λ1 þ
x2
m2
 λ2
1þ x2m2
 λ2 −
x1
m1
 λ1
1þ x1m1
 λ1
x2
m2
 λ2
1þ x2m2
 λ2 : ð16Þ2.3. Delta Score to Quantify the Deviation from the ZIP Model
The ZIP model was derived from the zero interaction potency per-
spective, but from Eq. (16) one can see that when modeling the dose–
response with logistic functions, the zero interaction from the ZIP
model corresponds to probabilistic independence. Following this line,
we further reasoned that a degree of drug interaction can be modeled
as the potency shifts captured by the dose–response curve parameters:
If one drug alters the potency of the other drug, then comparing the
dose–response curves of individual drugs and their drug combination
should give a quantitative measure of the interaction effect. Namely,
we ﬁtted the observed combination effect yc in a two-waymanner sim-
ilarly to (14) and (15):
y1←2c ¼
y2 þ x1m1←2
 λ1←2
1þ x1m1←2
 λ1←2 ¼
1
1þ m2x2
 λ2 þ
x1
m1←2
 λ1←2
1þ x1m1←2
 λ1←2 ; ð17Þ
y2←1c ¼
y1 þ x2m2←1
 λ2←1
1þ x2m2←1
 λ2←1 ¼
1
1þ m1x1
 λ1 þ
x2
m2←1
 λ2←1
1þ x2m2←1
 λ2←1 ; ð18Þ
wherem1→ 2 and λ1→ 2 are the projected potency and shape parameters
for drug 1 when adding x2; m2→ 1 and λ2→ 1 are those parameters de-
rived for drug 2 when adding x1 (see Fig. 2A for illustrations). We de-
ﬁned a delta score to capture the overall interaction potency shift by
taking an average deviation between yc and yZIP from Eqs. (14), (15),
(17) and (18):
δ θð Þ ¼ y
1→2
c −y
1→2
ZIP
2
þ y
2→1
c −y
2→1
ZIP
2
¼ 1
2
1
1þ m2x2
 λ2 þ
x1
m2→1
 λ2→1
1þ x1m2→1
 λ2→1 þ
1
1þ m1x1
 λ1 þ
x2
m1→2
 λ1→2
1þ x2m1→2
 λ1→2
0
BBBBBB@
1
CCCCCCA
−
x1
m1
 λ1
1þ x1m1
 λ1 þ
x2
m2
 λ2
1þ x2m2
 λ2 −
x1
m1
 λ1
1þ x1m1
 λ1
x2
m2
 λ2
1þ x2m2
 λ2
0
B@
1
CA;
ð19Þ
where the parameter set θ= {m1, m2, m1→2, m2→1, λ1, λ2, λ1→2, λ2→1}
can be estimated from the dose–response data, typically using the
least-squares method which is equivalent to a maximum likelihood es-
timate for normally distributed errors [13]. Score of δ=0, N0 or b0 cor-
responds to the zero interaction, synergy and antagonism, respectively.
We further showed that δ=0 also holds for a sham experiment where
two identical drugs are combined, i.e.,m1 =m2 and λ1 = λ2 (proof de-
tails in Appendix A2). From this perspective, we may consider the ZIP
model an integration of the Bliss independence and the Loewe additiv-
ity models.
2.4. Interaction Landscape Surface Plot Based on the Delta Score
As seen from Eq. (19), the delta scoring requires the parameters for
the dose–response curves both in monotherapy and in combination.
The estimation of these parameters requires at least three dose–re-
sponse data points, i.e., (y1, y2, yc) at (x1, x2, (x1, x2,)). However, for a re-
liable estimate, one would need more comprehensive response data
where multiple doses have been tested. High-throughput screening
has made it possible to efﬁciently probe a drug pair at multiple doses
in a full matrix. Therefore, a delta score can be calculated for each dose
combination in the matrix, which allows for a surface plot of delta
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Fig. 2. (A) Formulation of the ZIP model and the delta scoring illustrated in a dose–re-
sponse matrix. To evaluate the degree of interaction at a dose combination (x1, x2), the
midpoint m and the shape parameter λ from the individual drug responses (the ﬁrst col-
umn and the last row) as well as their combined effects at column x1 and row x2 are com-
pared. The delta scoring considers the changes ofm and λ for the dose–response curves
between drug 1 alone (the bottom row) and the combination after adding x2 (row x2),
as well as between drug 2 alone (the ﬁrst column) and the combination after adding x1
(column x1). (B) Scale and interpretation of the drug interaction scores. Each scoring
method determines a synergistic drug combination differently. The delta scoring quan-
tiﬁes the synergistic effects as the percentage inhibition values and thus a non-interaction
will correspond to delta value of 0. Alpha and HSA also have a score of 0 for non-interac-
tion,whereas for CI, beta and gamma scores, the reference score for non-interaction stands
at 1. CI, beta and gamma scores are left-bounded at 0. The directions of the interaction
scores are also different. For CI, beta and gamma, a lower score is more synergistic while
for delta, alpha and HSA it is the opposite interpretation.
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effects over the full dose matrix, which is more informative than what
a single summary score can provide. We utilized the surface plot of
the delta scores to visualize the interaction landscape for a drug combi-
nation, aiming to identify synergistic and antagonistic dose regions for
further dose optimization in a validation screen. It is worth noting that
a delta score has a unit of percentage inhibition (e.g., δ = 0.2 corre-
sponds to 20% of response beyond expectation). Therefore, the delta
scores are directly comparable within and between drug combinations.
This is also an important feature of our approach that facilitates efﬁcient
prioritization in a high-throughput setting.
2.5. The Mathews Griner Drug Combination Screening Dataset
To demonstrate the performance of the ZIP-based delta scoring, we
considered a recent cancer drug screen study involving ibrutinib in
combination with 466 compounds for the activated B-cell-like subtype
(ABC) of diffuse large B-cell lymphoma (DLBCL) [14]. Ibrutinib is asmall molecule targeting Bruton's tyrosine kinase (BTK) approved for
the treatment of mantle cell lymphoma and chronic lymphocytic leuke-
mia [16]. In this study, a high-throughput drug combination screening
was used to identify other compounds that can synergistically interact
with ibrutinib to improve its anticancer efﬁcacy and circumvent drug
resistance. For each drug pair, a 6 × 6 dose–response matrix design
was utilized, where the drug effect was measured as percentage of cell
viability using TMD8 cancer cell line. The raw combination data was
provided by the authors via personal communication, but can now be
downloaded from https://tripod.nih.gov/matrix-client/rest/matrix/
export/241. We transformed the original percentage viability data into
the percentage inhibition data before applying the drug combination
analysis to be compatible with the mathematical formulation deﬁned
in the Methods section.
We ran the ZIPmodel on the drug combination data and calculated a
summary delta scoreΔ for each drug pair by taking the average of all the
delta scores over its dose combinations, i.e., Δ ¼ 1n∑
n
i¼1
δ; where n is the
number of dose combinations and n=25 for a 6× 6 dose–responsema-
trix (monotherapy responses were removed). We compared the sum-
mary delta scores with the other scores derived from the HSA-, Bliss-
and Loewe-based models. For HSA and Bliss, there were existing scores
implemented in the original study [14], which were based on the fol-
lowing methods: 1) NumExcess is the number of wells in the dose ma-
trix that produced higher effect than both of the individual drug effects;
2) ExcessHSA is the sum of differences between the combination effect
and the expected HSA effect; 3) MedianExcess is the median of the HSA
excess; 4) ExcessCRX is an extension of the HSAmodel that was adjust-
ed by dilution factors; 5) LS3×3 is the ExcessHSA applied to a 3 × 3
block showing the best HSA synergy in the dose matrix; 6) Beta (β) is
the interaction parameter minimizing the deviance from the Bliss inde-
pendence model over all dose combinations deﬁned as argmin
β
ð
∑ð1−yc−βð1−y1Þð1−y2ÞÞ2Þ; and 7) Gamma (γ) is a combination of
HSA and Bliss models minimizing argmin
γ
ð
∑ð1−yc−γmaxð1−y1;1−y2ÞÞ2Þ: For the Loewe-based models, we
calculated the two common interaction indices CI (Eq. (8)) and alpha(a)
(Eq. (9)). The CI was calculated using an R package SYNERGY [13] and
the alpha score was estimated using the R package drc [12].
2.6. Statistical Signiﬁcance Testing for an Observed Delta Score
For a drug combination where multiple replicates are available, we
may take a two-step approach for the evaluation of statistical signiﬁ-
cance of the observed delta score at a given dose pair (x1, x2).First, we
may utilize non-linear regression ﬁtted with logistic functions to esti-
mate the parameters in θ.Then, we can utilize a bootstrapping method
by randomly sampling the parameter set θ from normal distributions
with their estimated means and variances, with which we calculated
delta using Eq. (19). This simulation can be repeated multiple times to
get a stable distribution of delta from which an asymptotic p-value
can be calculated as the proportion of the bootstrap samples with
delta higher than 0. Further, as long as the random sampling of delta fol-
lows approximately a normal distribution, 100(1− a)% conﬁdence in-
terval for delta can be calculated as
δ
∧
−z1−α=2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
var δð Þ=n
p
; δ
∧
þz1−α=2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
var δð Þ=n
p 
;
where z1 − a/2 is the 100(1− a / 2) percentile of the standard normal
distribution and α is the type I error that normally is set at 0.05 [17].
Since each of the 466 drug combinations in theMathews Griner data
was tested only once, the statistical procedure above cannot be imple-
mented as such in this dataset. However, because all of the drug combi-
nations involved ibrutinib, we can collect its replicated response data at
Fig. 3. Classiﬁcation accuracy of the drug interaction scoring methods. The ROC (receiver
operator characteristic) curves were plotted using a visual classiﬁcation of the raw drug
combination data, which was blinded to the quantitative scoring methods. The area
under the ROC curve (AUROC) is shown for each scoring method when classifying 112
synergistic and 91 antagonistic drug combinations. The statistical signiﬁcance between
the observed AUROCs can be found in Supplementary Table 2.
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monotherapy data can be further utilized to quantify the experimental
noise and extrapolated for the drug combination measurements (Sup-
plementary Fig. 1A). By assuming that the measurement uncertainty
depends on a speciﬁc concentration of ibrutinib, we generated random
samples for each drug combination according to normal distributions
N(yij, σi2), where yij is the observed drug combination response where
ibrutinib ith concentration is combined with the other drug at the jth
concentration;σi2 is the variance of the ibrutinib response at the ith con-
centration.We simulated 1,000 samples for each drug combination, and
calculated a resampled delta score, for which the statistical signiﬁcance
can be approximated.
3. Results
3.1. The Symmetry, Range and Robustness of the Delta Score
We proposed the delta score based on the ZIP model for evaluating
drug interaction effect at a given dose pair. For a dose–response matrix,
we utilized a summary delta score to average the overall interaction ef-
fect over all the dose pairs for a drug combination. For a comparative
analysis, we explored altogether ten drug interaction scoring methods,
i.e., NumExcess, ExcessHSA, MedianExcess, ExcessCRX, LS3×3, Beta,
Gamma, CI, Alpha and Delta. These scoringmethods can be represented
as an axis with a reference point for non-interaction (Fig. 2B). For beta,
gamma and CI, the reference score for non-interaction is 1 and a value
less than 1 indicates synergy. These scoringmethods are thus non-sym-
metric since the range of synergy is between 0 and 1, which is much
smaller than the range of antagonism which is [1,∞]. On the other
hand, delta, alpha and HSA-based scores have the reference point at 0
for non-interaction, which ﬁts more to the intuition that synergy and
antagonism should have opposite signs. Unlike CI and alpha which are
dimensionless, the delta score tells the percentage of cell inhibition
and thus can provide directly an estimate of the extra effect of a drug in-
teraction. For example, a delta of 0.1 would indicate that the drug com-
bination will produce on average 10% more of the cell inhibition
compared to the expected effect, while a delta of−0.1 would indicate
an antagonismwith the same level ofmagnitude. Such a symmetry can-
not be assumed for Loewe additive models (e.g., yCI = 1.1−
yLOEWE ≠ yLOEWE−yCI = 0.9, where yCI = 1.1 and yCI = 0.9 are the combina-
tion effects for CI = 1.1 and CI = 0.9, respectively). When comparing
delta with HSA, it is obvious that delta is more stringent to classify syn-
ergy, and therefore it ﬁts better with the observations that true syner-
gies are rare [18].
The ZIP model was successfully applied to the Mathews Griner data
consisting of 466 drug combinations, producing a summary delta score
for each dose–response matrix (Supplementary Table 1). Since these
drug combinations were not replicated, we carried out an ad-hoc simu-
lation procedure to derive asymptotic delta scores for each combination
by assuming that the measurement error follows a normal distribution
with zero mean and variance estimated from the ibrutinib single-com-
pound dose–responses (Supplementary Fig. 1A). We found that the
summary delta scores obtained from the real data are highly similar to
those from the simulated data (rank correlation = 0.97, root mean
square error = 1.02%, Supplementary Fig. 1B), indicating a high degree
of reproducibility in response to measurement errors. Further, the sim-
ulated scores showed a low level of dispersion (average median abso-
lute deviation = 3.07%), implying that a robust estimation can be
made when sufﬁcient number of replicate measurements are available.
3.2. Correlations With the Other Interaction Scores and Their Classiﬁcation
Accuracy
There is a general agreement between delta and most of the other
scorings reported in the original publication: the highest correlations
were found for ExcessHSA (rank correlation of −0.85), beta (rankcorrelation of−0.77) and gamma (rank correlation of−0.83) (Supple-
mentary Fig. 2). However, we found a large portion of drug combina-
tions (n = 135), where the CI cannot be calculated due to the
limitation of the Loewe-based models described in the Method section.
After the removal of such cases, the correlation between the summary
delta and CI was relatively poor (rank correlation of −0.5). We note
that the calculation of CI in the SYNERGY R package was done at a
ﬁxed-ratio level and therefore it utilized only the diagonal of a dose–re-
sponsematrix. Ignoring the rest of the dose–response datamakes the CI
calculationmore sensitive to outliers and therefore become less compa-
rable with the other scores which utilize the whole dose–response ma-
trix data. Similarly, the alpha score did not correlate well with delta
(rank correlation of 0.43), and we also found difﬁculties to run the drc
package on some of the combination data (n= 115 cases could not be
calculated).
Taken together, these comparative analyses suggested that delta
scoring was more consistent with the HSA- and Bliss-based models
than with the Loewe-based models. We also found that curve ﬁtting
pose frequent problems for the Loewe-based models, indicating that a
Loewe model might not be ﬂexible enough to cope with the high-
throughput data, where a dose–response curve cannot be always ﬁtted
with logistic functions. To further evaluate the accuracy of these scoring
models, we classiﬁed the 466 combinations into three interaction clas-
ses (synergistic, antagonistic and non-interaction), according to a visual
inspection of the dose–response matrix raw data. Altogether, 121 com-
binations were labeled as synergistic, including 10 out of 11 synergistic
combinations conﬁrmed in [14], and 91 antagonistic combinations. We
then performed the ROC analysis for themodel scorings (Fig. 3, Supple-
mentary Table 2), which showed that the delta scoring performed the
best in this dataset, followed by the beta, gamma and ExcessHSA scor-
ings. Consistent with the correlation results, the CI and alpha scorings
produced lower classiﬁcation accuracies.
Since therewere signiﬁcant portions of caseswherewe could not get
valid CI and alpha scores, we decided to focus next on the comparisons
between ZIP, HSA and Bliss models. The summary delta scores derived
Fig. 4. Density plots for beta, gamma and delta scores across the full set of 466 drug com-
binations in the Mathews Griner data. Beta and gamma scores tend to overestimate the
number of synergistic combinations (shaded areas), while delta minimizes the rate of
false positives by applying a threshold of 5% response, which is the typical noise level in
a large-scale drug combination experiment.
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to 0.7% of extra inhibition effect, which is quite close to its theoretic ref-
erence point at 0 (Table 1). The distribution also ﬁts to our expectation
that drug combinations in a high-throughput setting should be mostly
non-interactive. For the other models, the interaction score was more
shifted away from the theoretical reference point toward the synergistic
regions. For example, themedian and skewness of ExcessHSA scores are
−63.9 and−0.27, respectively, indicating thatmore drug combinations
were classiﬁed as synergistic in theHSAmodels. In particular, if we used
a delta cut-off 0.05 (corresponding to an average excess of 5% inhibition
in the combination) to classify the drug interaction, there were 74 syn-
ergistic combinations, which is much lower than the number of syner-
gistic combinations determined by the other scores (Fig. 4). For
example, using the beta score, one would identify 338 synergistic com-
binations with β b 1 and with γ b 1 this number becomes even higher
(n= 354). As the main purpose of the high-throughput drug combina-
tion screening is to prioritize potential synergistic drug combinations
for a secondary conﬁrmation screen, these results suggest the delta
scoring as a reliable approach to keep the prioritization process more
cost-efﬁcient and less error-prone.
3.3. Identiﬁcation of Clinically Relevant Synergy and Antagonism via the In-
teraction Landscapes
We next utilized the delta scores to visualize in more detail the syn-
ergistic and antagonistic patterns on the dose–response matrix (Fig. 5,
Supplementary Fig. 3). The top synergistic interaction was found with
ispinesib, which is a selective Kinesin spindle protein (KSP) inhibitor
that has entered clinical trials for many cancers [19]. The interaction be-
tween ispinesib and ibrutinib was almost universally synergistic over
the whole dose–response matrix, leading to a maximal combination ef-
fect close to 100% of cell inhibition at the higher concentrations of both
individual drugs. The strongest synergistic effect (40% inhibition) was
found within the region of dose combinations where iburutinib's dose
is ﬁxed at 0.78 nM (Fig. 5A). Such a landscape pattern indicated that
the dose of ispinesib can be lowered by 16-fold from its maximal
(2500 nM) to 156 nM while keeping the combination response at the
same level. Further, we found that the actual effect of combining
ispinesib at 156 nM and ibrutinib at 0.78 nM is able to achieve the
same effect compared to the combination of 2500 nM ispinesib and
0.78 nM ibrutinib. Taken together, the interaction landscape indicated
that the combination of ispinesib and ibrutinib might be able to achieve
a higher effect than individual drugs while maintaining acceptable
doses and hence side effects. Such an interaction landscapemight there-
fore provide a new way of detecting clinically relevant synergy beyond
what a binary classiﬁcation of drug interaction can answer. On the other
hand, the interaction landscape analysis also revealed many antagonis-
tic drug combinations. For example, the top antagonistic interaction oc-
curred between ibrutinib and canertinib, a potent EGFR/HER family
inhibitor. As can be seen from Fig. 5B, the strongest antagonism was
found centered at the dose combination of 12.5 nM of ibrutinib and
625 nM of canertinib. The antagonism was also clearly visible in theTable 1
Summary statistics of the drug interaction scores in the Mathews Griner data.
Score Median Mean Skewness Reference point
MedianExcess 66.46 66.29 −1.12 0
NumExcess 13.00 13.59 0.08 0
ExcessHSA −63.0 −86.50 −0.27 0
ExcessCRX −45.52 −83.74 −18.17 0
LS3×3 −5.72 −8.15 −0.88 0
Beta 0.99 0.98 −0.34 1
Gamma 0.98 0.97 −0.99 1
Delta 0.007 0.009 0.16 0dose–response matrix as the combination effect is almost universally
lower than the individual drug effects. Although from the cancer treat-
ment point of view, antagonistic drug combinations are often ignored,Ibrutinib (nM)
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Fig. 5. The top synergistic and antagonistic drug combinations identiﬁed from the
Mathews Griner data. (A) The ispinesib and ibrutinib combination. (B) The canertinib
and ibrutinib combination. For each combination, the interaction landscapes are shown
in both 2D and 3D.δ: the excess % inhibition beyond the expectation by the ZIP model;
Δ: the average δ scores over the dose–response matrix. The complete interaction land-
scapes for all the 466 drug combinations can be found in Supplementary Fig. 3.
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portance to understand the cross-talks between the cancer signaling
pathways, and these may also provide clinically important guidelines
to avoid administrating a drug combination that may interfere each
other by triggering such an antagonistic cross-talk in cancer.
High delta scores (N0.05 or 5%)were also conﬁrmed for several drug
combinations reported in the original Mathews Grinder study
interacting with ibrutinib [14], such as Bcl-2 family inhibitor
(navitoclax), PI3K pathway inhibitors (MK-2206, idelalisib (CAL-101),
dactolisib (BEZ-235) and everolimus), as well as with common chemo-
therapeutic agents (doxorubicin, dexamethasone, docetaxel and
plinabulin). The average delta score for these conﬁrmed drug combina-
tions was 0.1 (10.1%), which is signiﬁcantly higher than the average
(0.007 or 0.7%) of the total 466 combinations (Wilcoxon rank sum
test, p= 2.1 × 10−6). With their interaction landscapes available, it is
now possible to differentiate the drugs of same mechanisms in terms
of the interaction patterns. For these PI3K pathway inhibitors, we
found that their interaction patterns can be classiﬁed into two catego-
ries: ibrutinib-driven (together with AKT and mTOR inhibitors MK-
2206, everolimus and dactolisib), and PI3K inhibitor-driven (togetherA Δ=11.2%
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Fig. 6. The different interaction patterns for PI3K inhibitors and ibrutinib. (A) Ibrutinib-
driven synergy is triggered by a ﬁxed dose of ibrutinib and becomes visible at the full
dose ranges for a PI3K inhibitor, highlighted as a vertical box in the interaction landscape.
(B) In contrast, PI3K-driven synergy ismainly constrainedwithin a horizontal box aligned
with the dose.with the CLL-approved PI3Kδ inhibitor idelalisib) (Fig. 6). Take MK-
2206 as an example, higher delta scores were found for all the tested
doses when ibrutinib was ﬁxed at 0.78 nM. We may consider that
such a synergy was most likely initiated by ibrutinib. On the contrary,
the synergy region for idelalisib was mainly following the other direc-
tion in the landscape, producing a stable efﬁcacy boost for ibrutinib.
Therefore, one can attribute such a pattern as triggered by the mecha-
nism of PI3K inhibition. We also found that two pan-PI3K inhibitors in-
cluding pictilisib (GDC-0941) and apitolisib (GDC-0980) were showing
the ibrutinib-driven pattern in the combination, but with delta scores
lower than 0.05 (5%), and therefore were considered insigniﬁcant at
the whole dose-matrix level (Fig. 6). Such a diluted synergy effect
might be due to the limited speciﬁcity of such a pan-PI3K inhibition. Un-
fortunately, theMathews Griner data does not contain replicates for the
same drug combinations, which would have enabled evaluation of the
signiﬁcance of such interaction patterns using the statistical testing pro-
posed in the Method section. Despite these limitations in the example
data, our results suggest that the interaction landscape has the potential
to capture patterns that are related to their underlying target interac-
tions and thus warrants further mechanistic studies.
4. Discussion
Systematic evaluation of drug combination experiments to pinpoint
synergistic interactions is a challenging task. In this work, we examined
the limitations of the current reference models for assessing drug inter-
actions in the high-throughput setup, and developed a novel ZIP model
to capture the shift of interaction potency for a non-interactive drug
combination. The ZIP model takes the advantages of both the Loewe
and the Bliss models, aiming at a systematic assessment of various
types of drug interactions patterns that may arise in a high-throughput
drug combination screening. It utilizes the concept of zero interaction
between two drugs to derive the expected effect, where the potency
of the dose–response curve for one drug should remain unaltered
after adding the other drug. We proposed the delta scoring to capture
the deviation of the observed combination dose–response curves from
the expectation, which can be calculated efﬁciently with fewer assump-
tions on the actual dose–response relations. For facilitating more sys-
tematic analysis over the whole dose–response matrix, we
implemented a surface plot approach based on the delta scoring, to vi-
sualize the landscape of drug interaction over all the all tested dose
pairs. The detailed drug synergy patterns should provide improved in-
formation on the dose optimization that warrants further exploration.
These new features in the ZIP model allow for exploiting the rich data
from a dose–response matrix experiment, where two drugs are tested
at various dose pairs in a serially diluted manner.
Utilizing a public large-scale drug combination data [14], we have
shown that the delta score based on the ZIPmodel can reproduce the re-
ported synergistic combinations, while keeping the total number of syn-
ergistic combinations low, making it advantageous for the prioritization
purposes. The delta score is centered at 0 and symmetric, which makes
its interpretation more straightforward compared to the scoring based
on the Loewe additive models. On the other hand, the delta score also
considers the dose–response relationships of individual drugs and
drug combinations, and therefore becomesmore accurate at the charac-
terization of potency changes in drug interactions, compared to the rel-
atively simplistic HSA and Bliss independencemodels. Further, with the
help of the interaction landscape analysis, one can always search for the
particular patterns of synergy and antagonism within the dose combi-
nation matrices, and evaluate whether such a pattern is globally persis-
tent at clinically relevant doses, or present only for a speciﬁc region in
the dose matrix. We have also made available the R code and the dy-
namic report for running the calculation of delta score using the
Mathews Griner data as an example (Supplementary File 1).
Although the current ZIP-based delta scoring was formulated based
on the logistic curve ﬁtting for dose–response relationships, the same
512 B. Yadav et al. / Computational and Structural Biotechnology Journal 13 (2015) 504–513principle about characterizing potency shift can be derived irrespective
of the mathematical formulation of dose–responses. For example, with
the exponential family y=1− exp(−βx), the change in the parameter
β between the individual drugs and a drug combination can be used to
quantify the degree of interaction potency. Since the main focus of this
article was to introduce the ZIP concept, the mathematical extension
of the ZIP model for other curve ﬁtting functions is outside the scope
of the present work, but worth exploring in the future. While the cur-
rent ZIP model deals with the common phenotypic outcomes, such as
percentage of cell inhibition, the model can be readily extended to the
analysis of other functional phenotypes, such as the change of phos-
phorylation level of biomarkers in the downstream cancer pathways
[20]. Despite several potential extensions, the present ZIP model has al-
ready shown its ﬂexibility and interpretability when evaluating high-
throughput drug combination data. Further, the interaction landscape
analysis has also potential to extract detailed interaction patterns from
a dose–response matrix, which may eventually provide valuable novel
insights into how the mechanisms of these drugs are connected in the
context of cellular pathways.
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Appendix AAppendix A1
We prove that yZIP ¼
ð x1m1Þ
λ1
1þð x1m1Þ
λ1
þ ð
x2
m2
Þλ2
1þð x2m2Þ
λ2
−
ð x1m1Þ
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.
Let A ¼ ðm1x1 Þ
λ1 and B ¼ ðm2x2 Þ
λ2 then according to Eq. (14) and Eq. (15)
y1←2ZIP ¼
1
1þBþ1A
1þ1A
and y2←1ZIP ¼
1
1þAþ1B
1þ1B
. It can be hence derived that yZIP ¼ y1←2ZIP ¼
y1←2ZIP ¼ 1þAþB1þAþBþAB. Q.E.D
Appendix A2
We prove that for a sham experiment δ= 0.
In a sham experiment, both drugs have the same dose–effect curve,
denoted as
y ¼
x
m
 λ
1þ xm
 λ : ðA2:1ÞSince it is a Sham experiment, it holds that m1 = m2 = m1→ 2 =
m2→ 1 and λ1 = λ2 = λ1→ 2 = λ2→ 1. According to Eq. (19)
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Placing Eqs. (A2.3) and (A2.4) back into Eq. (A2.2) gives:
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Appendix A3
The derivation of the δ score for a full 4-parameter log-logistic func-
tion y ¼ EminþEmaxð xmÞ
λ
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